Buprenex and Sotalol Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using sotalol together with buprenorphine may have additive effects on lowering your blood pressure. You may experience dizziness, lightheadedness, headache, flushing, fainting, and fast or pounding heart beats. These effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor. The following also applies if you are receiving buprenorphine in the form of a skin patch for pain: Talk to your doctor before using the skin patch together with sotalol. Combining these medications can increase the risk of an irregular heart rhythm that may be serious, especially if you are on a higher dosage of the patch. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, or fast or pounding heartbeats during treatment with these medications, whether together or alone. Do not use more of these medications than what your doctor prescribed.

GENERALLY AVOID: Buprenorphine administered transdermally at a higher than recommended dosage has been associated with prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval such as sotalol may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In healthy volunteers, there was no difference in the effect of buprenorphine 10 mcg/hr administered transdermally on the QT interval compared to placebo. However, buprenorphine 40 mcg/hr (twice the maximum recommended dosage) was associated with a mean prolongation of the QT interval of 5.9 msec compared to placebo. Buprenorphine 20 mcg/hr was not studied. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: According to the product labeling, use of buprenorphine transdermal films should be avoided in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents. A dosage of 20 mcg/hr should not be exceeded in patients receiving the buprenorphine transdermal system. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.

MONITOR: Coadministration of sotalol and buprenorphine may result in additive effects on blood pressure and orthostasis. Buprenorphine can cause severe hypotension, and it may produce orthostatic hypotension in ambulatory patients. The risk is increased in patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or concurrent administration of drugs that compromise vasomotor tone.

MANAGEMENT: Caution is advised during coadministration of sotalol and buprenorphine. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

Buprenex

Generic Name: buprenorphine

Brand name: Buprenex, Belbuca, Probuphine, Butrans, Sublocade, Subutex

Synonyms: Buprenex (injection - Buprenex)

What is Buprenex?

Sotalol Tablets

Generic Name: sotalol

Brand name: Betapace, Betapace AF, Sorine, Sotalol Hydrochloride AF, Sotylize

Synonyms: Sotalol

What is Sotalol Tablets?